Graft-versus-host disease

New England Journal of Medicine

Volumn 324, Issue 10, 1991, Pages 667-674

  Epstein, Franklin H ^a   Ferrara, James L M ^a   Deeg, H Joachim ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b FRED HUTCHINSON CANCER RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; MONOCLONAL ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY;

BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; LYMPHOMA; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMAN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSPLANTATION, AUTOLOGOUS;

EID: 0025963233     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199103073241005     Document Type: Review

References (55)

1. van Bekkum DW, de Vries MJ. Radiation chimaeras. London; Logos Press, 1967.
2. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1966–67; 62:21–78.
3. Gowans JL. The fate of parental strain small lymphocytes in F1 hybrid rats. Ann N Y Acad Sci 1962; 99:432–55.
4. McGregor DD. Bone marrow origin of immunologically competent lymphocytes in the rat. J Exp Med 1968; 127:953–66.
5. Korngold R, Sprent J. T cell subsets in graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-vs.-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker, 1990:31–50.
6. Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986; 68:770–3.
7. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990; 322:510–7.
8. Hess AD, Fischer achéal. Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. Transplantation 1989; 48:895–900.
9. Spitzer TR. Transfusion-induced graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-vs.-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker, 1990:539–55.
10. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 1990; 323:315–21.
11. Juji T, Takahashi K, Shibata Y, et al. Post-transfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan. N Engl J Med 1989; 321: 56.
12. Deeg HJ, Cottier-Fox M. Clinical spectrum and pathophysiology of acute graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-vs.-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker, 1990:311–36.
13. Sale GE, Shulman HM. The pathology of bone marrow transplantation. New York: Masson, 1984.
14. Sale GE, Shulman HM, Galluci BB, Thomas ED. Young rete ridge keratinocytes are preferred targets in cutaneous graft-versus-host disease. Am J Pathol 1985; 118:278–87.
15. Thomas ED, Storb R, Gift RA, et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832–43, 895–902.
16. Vogelsang GB. Acute graft-versus-host disease. In: Champlin R, ed. Bone marrow transplantation. Norwell, Mass.: Kluwer Academic, 1990:55–77.
17. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57:267–76.
18. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69:204–17.
19. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74:1428–35.
20. Sullivan KM, Siadak MF, Withcrspoon RP. Cyclosporine treatment of chronic graft-versus-host disease following allogeneic bone marrow transplantation. Transplant Proc 1990; 22:1336–8.
21. Ghayur T, Seemayer T, Lapp WS. Histologic correlates of immune functional deficits in graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-vs.-host disease: immunology, pathophysiology and treatment. New York: Marcel Dekker, 1990:109–32.
22. Unanue ER, Allen PM. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 1987; 236:551–7.
23. Weiss A, Imboden JB. Cell surface molecules and early events involved in human T lymphocyte activation. Adv Immunol 1987; 41:1–38.
24. Nishizuka Y. Studies and perspectives of protein kinase C. Science 1986; 233:305–12.
25. Samelson LE, Patel MD, Weissman AM, Harford JB, Klausner RD. Antigen activation of murine T cells induces tyrosine phosphorylation of a polypeptide associated with the T cell antigen receptor. Cell 1986; 46:1083–90.
26. Weiss A. T lymphocyte activation. In: Paul WE, ed. Fundamental immunology. 2nd ed. New York: Raven Press, 1989:359–84.
27. Hemler ME. Adhesive protein receptors on hematopoietic cells. Immunol Today 1988; 9:109–13.
28. Ghayur T, Seemeyer TA, Kongshavn PAL, Gartner JG, Lapp WS. Graft-versus-host reactions in the beige mouse: an investigation of the role of host and donor natural killer cells in the pathogenesis of graft-versus-host disease. Transplantation 1987; 44:261–7.
29. Symington FW, Storb R. Mechanisms of tissue damage in human acute graft-versus-host disease. J Immunol Immunopharmacol 1989; 9:214–9.
30. Piguet PF. Tumor necrosis factor and graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-vs.-host disease: immunology, pathophysiology and treatment. New York: Marcel Dekker, 1990:225–76.
31. Ferrara JL, Guillen FJ, van Dijken PJ, Marion A, Murphy GF, Burakoff SJ. Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease. Transplantation 1989; 47:50–4.
32. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170:2081–95.
33. Maier T, Holda JH, Claman HN. Natural suppressor (NS) cells: members of the LGL regulatory family. Immunol Today 1986; 7:312–5.
34. Sykes M, Romick ML, Hoyles KA, Sachs DH. In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease and permits alloengraftment. J Exp Med 1990; 171:645–58.
35. Parkman R. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J Immunol 1986; 136:3543–8.
36. Rappeport J, Mihm M. Reinherz E, Lopansri S, Parkman R. Acute graft-versus-host disease in recipients of bone-marrow transplantation from identical twin donors. Lancet 1979; 2:717–20.
37. Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft-vs.-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 1985; 161:718–30.
38. Fischer achéal, Bcschorner WE, Hess AD. Requirements for the induction and adoptive transfer of cyclosporine-induced syngeneic graft-versus-host disease. J Exp Med 1989; 169:1031–41.
39. Martin PJ. Pharmacologic approaches for prevention and treatment of acute graft-versus-host disease. Clin Aspects Autoimmunity 1990; 4(2):8–22.
40. Culpepper J, Lee F. Glucocorticoid regulation of lymphokine production by murine T lymphocytes. In: Webb DR. Goeddel DV, eds. Lymphokines: molecular cloning and analysis of lymphokines. New York: Academic Press, 1987:275–89.
41. Kahan BD. Cyclosporine. N Engl J Med 1989; 321:1725–38.
42. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of mcthotrexate. N Engl J Med 1983; 309:1094–104.
43. Poynton CH. T cell depletion in bone marrow transplantation. Bone Marrow Transplant 1988; 3:265–79.
44. Gale RP, Reisner Y. Graft rejection and graft-versus-host disease: mirror images. Lancet 1986; 1:1468–70.
45. Vallera DA, Blazar BR. T cell depletion for graft-versus-host disease prophylaxis: a perspective on engraftment in mice and humans. Transplantation 1989; 47:751–60.
46. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108:806–14.
47. Truitt RL, LeFever AV, Shih CCY, Jeske JM. Martin TM. Graft-vs.-leukemia effect. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-vs.-host disease: immunology, pathophysiology. and treatment. New York: Marcel Dekker, 1990:177–204.
48. Sosman JA, Oettel KR, Smith SD, Hank JA, Fisch P, Sondel PM. Specific recognition of human leukemic cells by allogeneic T cells. II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood 1990; 75:2005–16.
49. Sullivan KM, Witherspoon RP, Storb R. et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72:546–54.
50. Vossen JM, Heidt PJ. Gnotobiotic measures for the prevention of acute graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft-vs.-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker, 1990:403–13.
51. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment. N Engl J Med 1983; 308:302–7.
52. Martin PJ, Hansen JA, Anasetti C, et al. Treatment of acute graft-versus-host disease with anti-CD3 monoclonal antibodies. Am J Kidney Dis 1988; 11:149–52.
53. Herve P, Wijdencs J. Bergerat JP, et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interlcukin2 receptor monoclonal antibody (B-B10). Blood 1990; 75:1017–23.
54. Tutschka PJ, Copelan EA. Experience with sandoglobulin in bone marrow transplantation. Int J Cell Cloning 1986; 4:181–8.
55. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323:705–12.